Teleflex (TFX)
NYSE:TFX
Want to see TFX full AI Analyst Report?
TFX Stock Chart & Stats
$131.58
-$2.38(-1.33%)
At close: 4:00 PM EST
$131.58
-$2.38(-1.33%)
Day’s Range― - ―
52-Week Range$100.18 - $139.67
Previous CloseN/A
Volume73.33K
Average Volume (3M)932.60K
Market Cap
$5.88B
Enterprise Value$5.74B
Total Cash (Recent Filing)$309.41M
Total Debt (Recent Filing)$171.44M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Jul 30, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend Yield1.11%
Share Statistics
EPS (TTM)-22.80
Shares Outstanding44,270,210
10 Day Avg. Volume689,029
30 Day Avg. Volume932,595
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit3.83
Enterprise Value/Ebitda-64.87
Forecast
1Y Price Target
$145.38Price Target Upside10.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)6.7
Revenue Forecast (FY)$2.29B
Bulls Say, Bears Say
Bulls Say
Portfolio Focus On Core MarketsDivesting non-core and volatile businesses allows Teleflex to concentrate on durable vascular and interventional markets, supporting steadier organic growth prospects.
Share Repurchases And Capital AllocationAnalyst expects aggressive share repurchases funded by divestiture proceeds and debt reduction to lift reported earnings per share and create upside for equity value.
Strategic Optionality From Board ActionsBoard willingness to consider acquisition proposals establishes a strategic value floor and increases the potential for value-enhancing transactions.
Bears Say
Leadership Vacancy And Governance RiskLack of a permanent chief executive creates strategic uncertainty and represents a material governance risk that could undermine investor confidence.
Revenue And Guidance UncertaintyConservative revenue guidance and uncertain timing of divestitures increase the risk that consensus earnings expectations are not met, pressuring the stock's valuation.
Transition And Execution RiskTemporary service agreements and ongoing restructuring expose the company to execution risk and could weigh on earnings while transition costs persist.
Teleflex News
TFX FAQ
What was Teleflex’s price range in the past 12 months?
Teleflex lowest stock price was $100.18 and its highest was $139.67 in the past 12 months.
What is Teleflex’s market cap?
Teleflex’s market cap is $5.88B.
When is Teleflex’s upcoming earnings report date?
Teleflex’s upcoming earnings report date is Jul 30, 2026 which is in 66 days.
How were Teleflex’s earnings last quarter?
Teleflex released its earnings results on May 07, 2026. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.214 by $0.176.
Is Teleflex overvalued?
According to Wall Street analysts Teleflex’s price is currently Undervalued.
Does Teleflex pay dividends?
Teleflex pays a Quarterly dividend of $0.34 which represents an annual dividend yield of 1.11%. See more information on Teleflex dividends here
What is Teleflex’s EPS estimate?
Teleflex’s EPS estimate is 1.27.
How many shares outstanding does Teleflex have?
Teleflex has 44,270,210 shares outstanding.
What happened to Teleflex’s price movement after its last earnings report?
Teleflex reported an EPS of $1.39 in its last earnings report, beating expectations of $1.214. Following the earnings report the stock price went up 6.857%.
Which hedge fund is a major shareholder of Teleflex?
Currently, no hedge funds are holding shares in TFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teleflex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$145.38 (10.48% Upside)
$145.38 (10.48% Upside)
Blogger Sentiment
Bullish
TFX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.02%
12-Months-Change
Fundamentals
Return on Equity
-28.27%
Trailing 12-Months
Asset Growth
-5.31%
Trailing 12-Months
Company Description
Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
TFX Company Deck
TFX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced call: management reported solid pro forma revenue growth, strategic progress on M&A, a large capital return plan and promising clinical trial enrollment, but results were tempered by significant margin pressure (470–510 bps declines), remediation and recall costs, stranded costs from planned separations, higher interest expense and temporary integration/disruption in Interventional. Management positioned many negatives as largely transient and highlighted expected improvement beginning in 2027.View all TFX earnings summariesTFX Stock 12 Month Forecast
Average Price Target
$145.38
▲(10.48% Upside)
Technical Analysis
Haemonetics
―
ICU Medical
―
Lemaitre Vascular
―
Merit Medical Systems
―
Bausch + Lomb Corporation
―
Ownership Overview
0.41% Insiders
41.07% Mutual Funds
20.04% Other Institutional Investors
16.21% Public Companies and
Individual Investors